GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (LTS:0J9P) » Definitions » Cyclically Adjusted Price-to-FCF

Incyte (LTS:0J9P) Cyclically Adjusted Price-to-FCF : 41.60 (As of Jun. 02, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Incyte Cyclically Adjusted Price-to-FCF?

As of today (2025-06-02), Incyte's current share price is $64.4843. Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $1.55. Incyte's Cyclically Adjusted Price-to-FCF for today is 41.60.

The historical rank and industry rank for Incyte's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LTS:0J9P' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 36.22   Med: 102.85   Max: 1631.5
Current: 41.33

During the past years, Incyte's highest Cyclically Adjusted Price-to-FCF was 1631.50. The lowest was 36.22. And the median was 102.85.

LTS:0J9P's Cyclically Adjusted Price-to-FCF is ranked better than
57.28% of 103 companies
in the Biotechnology industry
Industry Median: 48.91 vs LTS:0J9P: 41.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Incyte's adjusted free cash flow per share data for the three months ended in Mar. 2025 was $1.326. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.55 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Incyte Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Incyte's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted Price-to-FCF Chart

Incyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,375.45 148.70 78.38 50.28 48.76

Incyte Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.95 53.72 52.05 48.76 38.46

Competitive Comparison of Incyte's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Incyte's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted Price-to-FCF falls into.


;
;

Incyte Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Incyte's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=64.4843/1.55
=41.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Incyte's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.326/134.9266*134.9266
=1.326

Current CPI (Mar. 2025) = 134.9266.

Incyte Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.060 100.684 0.080
201509 -0.031 100.392 -0.042
201512 0.304 99.792 0.411
201603 0.477 100.470 0.641
201606 -0.335 101.688 -0.445
201609 0.405 101.861 0.536
201612 0.402 101.863 0.532
201703 -0.997 102.862 -1.308
201706 0.421 103.349 0.550
201709 0.089 104.136 0.115
201712 -0.542 104.011 -0.703
201803 0.039 105.290 0.050
201806 0.100 106.317 0.127
201809 0.807 106.507 1.022
201812 0.271 105.998 0.345
201903 0.633 107.251 0.796
201906 0.486 108.070 0.607
201909 1.319 108.329 1.643
201912 0.468 108.420 0.582
202003 -3.335 108.902 -4.132
202006 1.023 108.767 1.269
202009 0.591 109.815 0.726
202012 0.255 109.897 0.313
202103 0.712 111.754 0.860
202106 0.480 114.631 0.565
202109 1.003 115.734 1.169
202112 0.364 117.630 0.418
202203 0.891 121.301 0.991
202206 0.726 125.017 0.784
202209 1.198 125.227 1.291
202212 1.166 125.222 1.256
202303 -0.587 127.348 -0.622
202306 1.326 128.729 1.390
202309 0.605 129.860 0.629
202312 0.642 129.419 0.669
202403 0.921 131.776 0.943
202406 -2.893 132.554 -2.945
202409 1.497 133.029 1.518
202412 1.759 133.157 1.782
202503 1.326 134.927 1.326

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Incyte  (LTS:0J9P) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Incyte Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Industry
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines